Literature DB >> 22446084

Microarray gene expression analysis of fixed archival tissue permits molecular classification and identification of potential therapeutic targets in diffuse large B-cell lymphoma.

Kim Linton1, Christopher Howarth, Mark Wappett, Gillian Newton, Cynthia Lachel, Javeed Iqbal, Stuart Pepper, Richard Byers, Wing John Chan, John Radford.   

Abstract

Refractory/relapsed diffuse large B-cell lymphoma (DLBCL) has a poor prognosis. Novel drugs targeting the constitutively activated NF-κB pathway characteristic of ABC-DLBCL are promising, but evaluation depends on accurate activated B cell-like (ABC)/germinal center B cell-like (GCB) molecular classification. This is traditionally performed on gene microarray expression profiles of fresh biopsies, which are not routinely collected, or by immunohistochemistry on formalin-fixed, paraffin-embedded (FFPE) tissue, which lacks reproducibility and classification accuracy. We explored the possibility of using routine archival FFPE tissue for gene microarray applications. We examined Affymetrix HG U133 Plus 2.0 gene expression profiles from paired archival FFPE and fresh-frozen tissues of 40 ABC/GCB-classified DLBCL cases to compare classification accuracy and test the potential for this approach to aid the discovery of therapeutic targets and disease classifiers in DLBCL. Unsupervised hierarchical clustering of unselected present probe sets distinguished ABC/GCB in FFPE with remarkable accuracy, and a Bayesian classifier correctly assigned 32 of 36 cases with >90% probability. Enrichment for NF-κB genes was appropriately seen in ABC-DLBCL FFPE tissues. The top discriminatory genes expressed in FFPE separated cases with high statistical significance and contained novel biology with potential therapeutic insights, warranting further investigation. These results support a growing understanding that archival FFPE tissues can be used in microarray experiments aimed at molecular classification, prognostic biomarker discovery, and molecular exploration of rare diseases.
Copyright © 2012 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22446084     DOI: 10.1016/j.jmoldx.2012.01.008

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  13 in total

1.  Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens.

Authors:  Christopher D Carey; Daniel Gusenleitner; Bjoern Chapuy; Alexandra E Kovach; Michael J Kluk; Heather H Sun; Rachel E Crossland; Chris M Bacon; Vikki Rand; Paola Dal Cin; Long P Le; Donna Neuberg; Aliyah R Sohani; Margaret A Shipp; Stefano Monti; Scott J Rodig
Journal:  J Mol Diagn       Date:  2014-11-07       Impact factor: 5.568

2.  Diffuse large B-cell lymphoma: sub-classification by massive parallel quantitative RT-PCR.

Authors:  Xuemin Xue; Naiyan Zeng; Zifen Gao; Ming-Qing Du
Journal:  Lab Invest       Date:  2014-11-24       Impact factor: 5.662

Review 3.  Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?

Authors:  Sarah Barton; Eliza A Hawkes; Andrew Wotherspoon; David Cunningham
Journal:  Oncologist       Date:  2012-10-18

4.  Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047.

Authors:  Alexandra M Levine; Ariela Noy; Jeannette Y Lee; Wayne Tam; Juan Carlos Ramos; David H Henry; Samir Parekh; Erin G Reid; Ronald Mitsuyasu; Timothy Cooley; Bruce J Dezube; Lee Ratner; Ethel Cesarman; Anil Tulpule
Journal:  J Clin Oncol       Date:  2012-11-19       Impact factor: 44.544

5.  Integrated analysis of 10 lymphoma datasets identifies E2F8 as a key regulator in Burkitt's lymphoma and mantle cell lymphoma.

Authors:  An-Ping Yang; Leyna G Liu; Min-Min Chen; Fang Liu; Hua You; Lian Liu; Hua Yang; Yang Xun; Jing Liu; Rui-Xue Wang; David D Brand; Dahai Liu; Song Guo Zheng; Wen-Xing Li
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

Review 6.  Role of Biobanks for Cancer Research and Precision Medicine in Hepatocellular Carcinoma.

Authors:  Peyda Korhan; Sanem Tercan Avcı; Yeliz Yılmaz; Yasemin Öztemur Islakoğlu; Neşe Atabey
Journal:  J Gastrointest Cancer       Date:  2021-11-22

Review 7.  From drug discovery to biomarker-driven clinical trials in lymphoma.

Authors:  Anas Younes; Donald A Berry
Journal:  Nat Rev Clin Oncol       Date:  2012-09-11       Impact factor: 66.675

Review 8.  Does the GH/IGF-1 axis contribute to skeletal sexual dimorphism? Evidence from mouse studies.

Authors:  Zhongbo Liu; Subburaman Mohan; Shoshana Yakar
Journal:  Growth Horm IGF Res       Date:  2015-12-31       Impact factor: 2.372

9.  Dysfunction of the mTOR pathway is a risk factor for Alzheimer's disease.

Authors:  Sharon C Yates; Amen Zafar; Paul Hubbard; Sheila Nagy; Sarah Durant; Roy Bicknell; Gordon Wilcock; Sharon Christie; Margaret M Esiri; A David Smith; Zsuzsanna Nagy
Journal:  Acta Neuropathol Commun       Date:  2013-05-08       Impact factor: 7.801

10.  Quantitative proteomic analysis of cultured skin fibroblast cells derived from patients with triglyceride deposit cardiomyovasculopathy.

Authors:  Yasuhiro Hara; Naoko Kawasaki; Ken-ichi Hirano; Yuuki Hashimoto; Jun Adachi; Shio Watanabe; Takeshi Tomonaga
Journal:  Orphanet J Rare Dis       Date:  2013-12-21       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.